Dapsone in the Treatment of Epidermolysis Bullosa Acquisita Long - Term Follow - Up
Journal: International Journal of Clinical Dermatology & Research (IJCDR) (Vol.04, No. 05)Publication Date: 2016-12-27
Authors : Elloudi S; El Mahi H; Salim G; Mernissi FZ;
Page : 104-106
Keywords : Epidermolysis Bullosa Acquisita; Dapsone;
Abstract
Epidermolysis bullosa acquisita (EBA) is a rare, acquired, chronic subepidermal bullous disease of the skin and mucosa characterized by autoantibodies to type VII collagen structures, a major component of anchoring fibrils, that attach the epidermis onto the dermis. The treatment of EBA is based on anecdotal reports in the literature with systemic therapies. We report a case of EBA successfully treated by dapsone.
Other Latest Articles
- Oral Health Issues in Psoriasis: An Overview of the Literature
- Primary Cutaneous Large B Cell Lymphoma, Leg Type: Good Evolution of A Particular Location
- Paraneoplastic Dermatomyositis: About 9 Patients
- Effect of ‘Treating Winter Disease in Summer’ Prescription on Skin Immune Barrier and Systemic Immunity in a Guinea Pig Model of Asthma
- Stevens - Johnson Syndrome Induced by Sorafenib for Hepatocellular Carcinoma
Last modified: 2017-05-26 20:30:40